首页期刊导航|癌症生物学与医学（英文版）
期刊信息/Journal information
癌症生物学与医学（英文版）
癌症生物学与医学（英文版）

郝希山

季刊

2095-3941

editor@cancerbiomed.org

022-23522919

300060

天津市河西区体院北环湖西路天津市肿瘤医院C座综合楼三楼

癌症生物学与医学（英文版）/Journal Cancer Biology & MedicineCSCDCSTPCD北大核心SCI
查看更多>>Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:● Cancer epigenetics● Cancer stem cell● Improved in vivo and in vitro cancer models● Cancer prevention and epidemiology● Biomarkers for predicting drug response● Mechanism of drug sensitivity and resistance● New approaches for cancer detection and diagnosis● Oncology clinical trials● Targeted therapy● Multidisciplinary treatment for cancerAuthor benefits: ● Easy online submission via Editorial Manager● Efficient and professional peer-review by expert referees from around the world● Rapid pre-print online publication● No charge for publication and Open Access● International visibility - the journal is available free online
正式出版
收录年代

    Innate IgM antibodies to mannose in patients with gastric cancer

    Maxim Petrovich NikulinNadezhda Vladimirovna ShilovaAlexander Dmitrievich LipatnikovIvan Sokratovich Stilidi...
    193-197页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Peptide drugs:a new direction in cancer immunotherapy

    Xinghua SuiXiaoshuang NiuXiuman ZhouYanfeng Gao...
    198-203页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Reducing the global cancer burden with gastrointestinal screening:China's 30 years practice

    Lei YangLi FengYong ZhuNing Wang...
    204-212页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Cervical cancer prevention in China:where are we now,and what's next?

    Huijiao YanQiankun WangYoulin Qiao
    213-217页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Current status of early gastric cancer screening research

    Can HuLi YuanXiangdong Cheng
    218-222页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    A retrospective analysis of mature T-and NK-cell lymphomas

    Junlei JiaXiaohui WangZheng SongShen Meng...
    223-229页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer

    Hantao ZhangDan DengShujun LiJing Ren...
    230-251页
    查看更多>>摘要：Lung cancer is the most common and fatal malignant disease worldwide and has the highest mortality rate among tumor-related causes of death.Early diagnosis and precision medicine can significantly improve the survival rate and prognosis of lung cancer patients.At present,the clinical diagnosis of lung cancer is challenging due to a lack of effective non-invasive detection methods and biomarkers,and treatment is primarily hindered by drug resistance and high tumor heterogeneity.Liquid biopsy is a method for detecting circulating biomarkers in the blood and other body fluids containing genetic information from primary tumor tissues.Bronchoalveolar lavage fluid(BALF)is a potential liquid biopsy medium that is rich in a variety of bioactive substances and cell components.BALF contains information on the key characteristics of tumors,including the tumor subtype,gene mutation type,and tumor environment,thus BALF may be used as a diagnostic supplement to lung biopsy.In this review,the current research on BALF in the diagnosis,treatment,and prognosis of lung cancer is summarized.The advantages and disadvantages of different components of BALF,including cells,cell-free DNA,extracellular vesicles,and microRNA are introduced.In particular,the great potential of extracellular vesicles in precision diagnosis and detection of drug-resistant for lung cancer is highlighted.In addition,the performance of liquid biopsies with different body fluid sources in lung cancer detection are compared to facilitate more selective studies involving BALF,thereby promoting the application of BALF for precision medicine in lung cancer patients in the future.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors:from gastrointestinal cancer analysis to pan-cancer validation

    Junya YanShibo WangJing ZhangQiangqiang Yuan...
    252-266页
    查看更多>>摘要：Objective:DNA damage response(DDR)deficiency has emerged as a prominent determinant of tumor immunogenicity.This study aimed to construct a DDR-related immune activation(DRIA)signature and evaluate the predictive accuracy of the DRIA signature for response to immune checkpoint inhibitor(ICI)therapy in gastrointestinal(GI)cancer.Methods:A DRIA signature was established based on two previously reported DNA damage immune response assays.Clinical and gene expression data from two published GI cancer cohorts were used to assess and validate the association between the DRIA score and response to ICI therapy.The predictive accuracy of the DRIA score was validated based on one ICI-treated melanoma and three pan-cancer published cohorts.Results:The DRIA signature includes three genes(CXCL10,IDO1,and IFI44L).In the discovery cancer cohort,DRIA-high patients with gastric cancer achieved a higher response rate to ICI therapy than DRIA-low patients(81.8%vs.8.8%;P<0.001),and the predictive accuracy of the DRIA score[area under the receiver operating characteristic curve(AUC)= 0.845]was superior to the predictive accuracy of PD-L1 expression,tumor mutational burden,microsatellite instability,and Epstein-Barr virus status.The validation cohort demonstrated that the DRIA score identified responders with microsatellite-stable colorectal and pancreatic adenocarcinoma who received dual PD-1 and CTLA-4 blockade with radiation therapy.Furthermore,the predictive performance of the DRIA score was shown to be robust through an extended validation in melanoma,urothelial cancer,and pan-cancer.Conclusions:The DRIA signature has superior and robust predictive accuracy for the efficacy of ICI therapy in GI cancer and pan-cancer,indicating that the DRIA signature may serve as a powerful biomarker for guiding ICI therapy decisions.
      原文链接:
    • NETL
    • NSTL
    • 万方数据